Dermatomyositis: An Update on Diagnosis and Treatment Dermatomyositis: An Update on Diagnosis and Treatment
Dermatomyositis is both a diagnostic and therapeutic challenge. This primer presents a review of its pathophysiology with a focus on myositis-specific autoantibodies and their associated phenotypes.American Journal of Clinical Dermatology
Publication date: Available online 2 July 2020Source: Practical Radiation OncologyAuthor(s): Kuczmarska-Haas A, Burr AR, Witt JS, Francis DM, Ali H, Sonneborn H, Mahadevan A, Brower JV
Authors: Chandra T, Aggarwal R Abstract INTRODUCTION: Currently, there are no proven drugs that are FDA approved for the treatment of dermatomyositis (DM), even though multiple clinical trials are ongoing to evaluate safety and efficacy of novel therapeutics in DM. The purpose of this review is to highlight the biological plausibility, existing clinical evidence as well as completed and ongoing clinical trials for various drugs in pipeline for development for use in dermatomyositis. AREAS COVERED: The drugs with the strongest evidence have been included in this review with a focus on the mechanism of their acti...
PMID: 32608029 [PubMed - as supplied by publisher]
Arthritis&Rheumatology, Volume 72, Issue 7, Page 1236-1236, July 2020.
Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis: A Case Report. Intern Med. 2020 Jun 23;: Authors: Nakanishi Y, Yamaguchi K, Yoshida Y, Sakamoto S, Horimasu Y, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Hirata S, Fujitaka K, Hamada H, Sugiyama E, Hattori N Abstract Anti-transcriptional intermediary factor 1γ (anti-TIF1γ) antibody-positive dermatomyositis (DM) is strongly associated with cancer, although the mechanism of action is still unclear. We herein describe the first known case of an 80-year-o...
A man who was diagnosed with rheumatoid arthritis (RA) five years ago sees his rheumatologist for a follow-up visit. Fortunately, his arthritis is well controlled through medication. He can walk and do all his daily activities without pain. But over the past six months, he’s been feeling short of breath when climbing stairs. He has an annoying dry cough, too. COVID-19? That’s ruled out quickly. But a CT scan of his chest reveals early fibrosis (scarring) of the lungs, most likely related to rheumatoid arthritis. “I can finally walk normally, and now I can’t breathe when I walk!” says the frust...
Dermatomyositis(DM) is an autoimmune systemic disease that most often affects skin and muscle. The pathogenesis of cellular skin inflammation has yet to be investigated. Previous work revealed a type 1 interferon gene signature characterized predominantly by interferon-beta ( β). To investigate the type 1 interferon signature, we identified pathways and cellular phenotypes in a subset of DM patients. 5 Healthy control (HC) and 5 DM formalin-fixed, paraffin-embedded (FFPE) samples obtained from trunk, arm, or leg were stained with a panel of 35 metal conjugated antibodie s.
Dermatomyositis (DM) is an acquired inflammatory myopathy characterized by chronic skin inflammation. The pathogenesis of DM is still unclear. Extracellular vesicles (EVs) are lipid bilayer membrane vesicles existing in various bodily fluids and implicated in the pathogenesis of autoimmune diseases. As type I interferons, specifically IFN-b, are uniquely elevated in DM, and Stimulator of interferon genes (STING) works as a critical sensor and adaptor in type I IFN signaling, we hypothesized that EVs derived from DM patients ’ plasma might trigger STING-mediated proinflammatory effects.